3:41 PM · 7 June 2021

Biogen trading paused after company received approval for its Alzheimer's drug

Biogen (BIIB.US) stock has been halted  after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.

Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5

17 November 2026, 9:36 PM

Nvidia rebounds 4% after earnings 🔼 Can the AI giant lift Wall Street?

17 November 2026, 6:27 PM

Shares of Nike drop despite business turnaround 🚩Disney and Home Depot after earnings reports

17 November 2026, 3:03 PM

US Open: Wall Street on Edge Ahead of Nvidia Earnings 🚩 Could Rising Oil Prices Weigh on Stocks?

17 November 2026, 7:00 AM

Nvidia Preview: Strong Results, Uncertain Future

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits